Evidence map›Paper›PMID 42356515›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Engineering Selenium-Chitosan Nanoparticles for Enhanced Hepatic Delivery of Sunitinib and Improved In Vitro Anticancer Activity in Hepatocellular Carcinoma Models.

Ahmed S G Srag El-Din, Eman Hamza, Ahmed Y Kira, Sameh Saber, Mona H Zohny, Ohoud Y Alshehri, Reham A Al-Dhelaan, Eslam Osama Mohamed, Heba I Elagamy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ahmed S G Srag El-DinDepartment of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.ORCID 0000-0002-9924-3154
Eman HamzaDepartment of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia.
Ahmed Y KiraDepartment of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.ORCID 0000-0003-1495-0480
Sameh SaberDepartment of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.ORCID 0000-0002-5070-7851
Mona H ZohnyDepartment of Biochemistry, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.ORCID 0009-0008-2099-5793
Ohoud Y AlshehriDepartment of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia.
Reham A Al-DhelaanDepartment of Biochemistry, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia.ORCID 0000-0002-3939-5607
Eslam Osama MohamedDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, 53100 Siena, Italy.
Heba I ElagamyDepartment of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt.

Funding

Imam Mohammad ibn Saud Islamic University IMSIU-DDRSP2601
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cytotoxicityhepatic distributionhepatocellular carcinomaMDR-HepG2 cellsselenium–chitosan nanoparticlessunitinib

Identifiers

PMID42356515
PMCPMC13304551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.